The company’s revenue from operations rose 42 per cent to Rs 71.09 crore in the March quarter compared to Rs 50.24 crore in the year-ago period, a statement said.
For the full fiscal year ended on March 31, 2026, the company posted a 74 per cent rise in net profit to Rs 30.48 crore against Rs 17.50 crore in the previous financial year.
Revenue jumped 42 per cent to Rs 251.73 crore in FY26 from Rs 177.58 crore in FY25, it added.
The fourth quarter underlined the increasing importance of oncology in the overall growth strategy, as the division continues to scale up and gradually shape the future growth profile, Sakar Managing Director Sanjay Shah said, adding that the company completed more than 60 business contracts with oncology products. PTI